IDIX - Idenix Pharmaceuticals Stock Price, News & Analysis

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Idenix Pharmaceuticals (NASDAQ:IDIX)

Idenix Pharmaceuticals logoIdenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company, as of December 31, 2012, was developing nucleotide polymerase inhibitors and NS 5A inhibitors to inhibits HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A Inhibitors. On January 25, 2013, the Company entered into a non-exclusive collaboration agreement with Janssen Pharmaceuticals, Inc for the clinical evaluation of all oral DAA HCV combination therapies.

Industry, Sector and Symbol

Industry Biotechnology


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Annual DividendN/A
Dividend YieldN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Frequently Asked Questions for Idenix Pharmaceuticals (NASDAQ:IDIX)

What is Idenix Pharmaceuticals' stock symbol?

Idenix Pharmaceuticals trades on the NASDAQ under the ticker symbol "IDIX."

Who are some of Idenix Pharmaceuticals' key competitors?

How do I buy Idenix Pharmaceuticals stock?

Shares of Idenix Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Idenix Pharmaceuticals?

Idenix Pharmaceuticals' mailing address is 320 Bent St, CAMBRIDGE, MA 02141-2025, United States. The biopharmaceutical company can be reached via phone at +1-617-9959800.

MarketBeat Community Rating for Idenix Pharmaceuticals (IDIX)

Community Ranking:  1.2 out of 5 (star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  168 (Vote Underperform)
Total Votes:  223
MarketBeat's community ratings are surveys of what our community members think about Idenix Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Idenix Pharmaceuticals (NASDAQ:IDIX)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Idenix Pharmaceuticals (NASDAQ:IDIX)

Price Target History for Idenix Pharmaceuticals (NASDAQ:IDIX)

Analysts' Ratings History for Idenix Pharmaceuticals (NASDAQ:IDIX)

No equities research coverage for this company has been tracked by


Earnings History and Estimates Chart for Idenix Pharmaceuticals (NASDAQ:IDIX)

Earnings by Quarter for Idenix Pharmaceuticals (NASDAQ:IDIX)

Earnings History by Quarter for Idenix Pharmaceuticals (NASDAQ IDIX)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2014Q214($0.22)($0.43)($26.07) millionViewN/AView Earnings Details
5/1/2014Q114($0.19)($0.24)$0.22 million($3.01) millionViewN/AView Earnings Details
2/27/2014Q413($0.22)($0.21)$0.15 million$0.50 millionViewN/AView Earnings Details
2/25/2013Q412($0.17)($0.17)$0.74 million$0.33 millionViewN/AView Earnings Details
11/1/2012Q312($0.17)$0.03$2.60 million$32.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Idenix Pharmaceuticals (NASDAQ:IDIX)

No earnings estimates for this company have been tracked by


Dividend History for Idenix Pharmaceuticals (NASDAQ:IDIX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Idenix Pharmaceuticals (NASDAQ IDIX)

Insider Trades by Quarter for Idenix Pharmaceuticals (NASDAQ:IDIX)

Insider Trades by Quarter for Idenix Pharmaceuticals (NASDAQ IDIX)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/31/2014Baupost Group Llc/Mamajor shareholderBuy16,420,241$6.50$106,731,566.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Idenix Pharmaceuticals (NASDAQ IDIX)

Belgian scientists claim Delaware wrongly seized, sold stockBelgian scientists claim Delaware wrongly seized, sold stock - October 13 at 7:33 PM
Head-To-Head Analysis: Idenix Pharmaceuticals (IDIX) versus Grifols, (GRFS)Head-To-Head Analysis: Idenix Pharmaceuticals (IDIX) versus Grifols, (GRFS) - September 7 at 2:28 AM
Heres where Mercks new Cambridge research facility will be locatedHere's where Merck's new Cambridge research facility will be located - July 13 at 4:30 PM
3 Important Questions We Want Answered When Merck Reports Its Q2 Results3 Important Questions We Want Answered When Merck Reports Its Q2 Results - July 27 at 9:02 AM
Activists want imminent retirement of Ariad CEOActivists want 'imminent retirement' of Ariad CEO - February 20 at 11:24 AM

Social Media



Idenix Pharmaceuticals (NASDAQ IDIX) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.